04:23 AM EST, 12/09/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday that the Darzalex Faspro-based regime "significantly" improved overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma.

The company said the results were based on expanded data from the phase 3 study and a post hoc analysis of clinically relevant subgroups.

The data showed that adding Darzalex Faspro to the standard treatment regimen of bortezomib, lenalidomide and dexamethasone leads to more profound minimal residual disease negativity and significantly improved progression-free survival compared with the standard treatment alone, the company said.

Studies showed 85% of patients who achieved minimal residual disease negativity with Darzalex Faspro were progression-free after 4.5 years, the company said, adding that subgroup analyses from the phase 3 study showed higher rates of minimal residual disease-negative conversion in patient groups more severely affected by multiple myeloma.